Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist

Latha Vairavan

CFO at Arcutis Biotherapeutics, Inc. (ARQT)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $148K

Reported trades

Filed Stock Type Shares Price Value Since
May 13SEC ARQTArcutis Biotherapeutics, Inc. Sell Plan 43585,978 held (−1%) $21.05 $9K +26.3%
May 6SEC ARQTArcutis Biotherapeutics, Inc. Sell Plan 1,34186,413 held (−2%) $23.61 $32K +12.6%
Mar 3SEC ARQTArcutis Biotherapeutics, Inc. Sell Plan 2,77287,835 held (−3%) $25.16 $70K +5.6%
Mar 3SEC ARQTArcutis Biotherapeutics, Inc. Sell Plan 8187,754 held (−0%) $25.91 $2K +2.6%
Feb 4SEC ARQTArcutis Biotherapeutics, Inc. Sell Plan 1,32063,607 held (−2%) $25.50 $34K +4.2%
Nov 5SEC ARQTArcutis Biotherapeutics, Inc. Sell Plan 8864,927 held (−0%) $24.72 $2K +7.5%
  • Sell

    CFO Latha Vairavan sold $9K of ARQT at $21.05 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Latha Vairavan sold $32K of ARQT at $23.61 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Latha Vairavan sold $70K of ARQT at $25.16 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Latha Vairavan sold $2K of ARQT at $25.91 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Latha Vairavan sold $34K of ARQT at $25.50 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Latha Vairavan sold $2K of ARQT at $24.72 — pre-scheduled 10b5-1 plan sale.